#USA #San Diego #Cancer Vaccine #NEUVOGEN #NGEN-143

NEUVOGEN Presents Innovative Vaccine Findings at AACR Annual Meeting

On April 29, 2025, NEUVOGEN, Inc., a biotechnology firm based in San Diego, made significant waves at the American Association of Cancer Research (AACR) annual meeting by revealing promising data about its next-generation whole tumor cell vaccine, dubbed NGEN-143. This vaccine has the potential to activate T cells that can recognize a diverse array of antigens, setting it apart from existing cancer vaccines in the market today.

According to Todd Binder, the Chief Executive Officer of NEUVOGEN, “These findings support that NGEN-143 can deliver an unprecedented breadth of targets and activate cytotoxic T cells, making it a superior potential option for patients.” The organization has set its sights on utilizing this novel vaccine to help patients suffering from non-small cell lung cancer (NSCLC).

Key Findings of NGEN-143

The data presented by NEUVOGEN highlighted several compelling aspects of the NGEN-143 vaccine:

1. Broad T Cell Activation: In a fully human in vitro system, the vaccine was found to expand effector T cells aimed at a wide range of tumor-associated antigens and neo-antigens across varied HLA types.
2. Dominance of Cytotoxic T Cells: NGEN-143 demonstrated that its response is primarily driven by CD8+ T cells, with no signs of competition among antigens, thereby indicating a strong immune response. Furthermore, the CD4+ T cell activation leaned towards the Th1 subset, which is associated with better anti-tumor activity.
3. Efficient Tumor Cell Killing: Activated T cells from the NGEN-143 treatment were capable of efficiently killing human tumor cells via a caspase-3 dependent mechanism, a critical process in programmed cell death.
4. Tumor Growth Inhibition in Animal Models: In an 'immune warm' CT26 mouse tumor model, NGEN-143 not only inhibited tumor growth but also promoted durable immune memory, showcasing potential long-term benefits after rechallenge. It also showed improved survival rates when combined with a PD-1 blockade (αPD1) compared to using αPD1 alone.
5. Enhanced Survival in Immune Cold Models: Further testing in the 'immune cold' B16F10 mouse model reinforced NGEN-143's ability to curtail tumor growth and enhance overall survival, particularly when combined with αPD1 treatment.

Upcoming Presentation and Accessibility

Dr. Bernadette Ferraro, the Vice President of Immuno-oncology at NEUVOGEN, is scheduled to present these findings in greater detail during a session at the AACR meeting set for April 29, from 200 to 500 PM CT. Attendees can expect a comprehensive discussion on how this optimized, off-the-shelf whole tumor cell vaccine may provide significant clinical benefits for patients afflicted with NSCLC.

For those unable to attend the conference, NEUVOGEN plans to make the poster available for download on their website at neuvogen.com/our-science following the event's conclusion.

About NEUVOGEN

Founded in San Diego, NEUVOGEN, Inc. is dedicated to developing advanced whole cell cancer vaccine therapies. The company prioritizes incorporating an extensive combination of tumor-associated and tumor-specific antigens into their vaccines. As a result, their next-generation therapies aim to target a significantly larger percentage of cancer cells within solid tumors than their predecessors. NEUVOGEN's overarching mission is to harness the body's immune system to combat not just primary tumors but also micrometastases, metastatic disease, and to delay relapses associated with both early and late-stage cancer. This innovative approach aspires to extend patients' lives with minimal side effects.

About NGEN-143

NEUVOGEN's flagship product, NGEN-143, is specifically engineered for patients diagnosed with non-small cell lung cancer. The formulation comprises six allogeneic tumor cell lines that have been genetically modified to include NEUVOGEN's proprietary activation technology. This modification broadens the spectrum of accessible tumor antigens, making NGEN-143 an off-the-shelf product aimed at connecting more patients with promising treatments.

For more details about NEUVOGEN's research and development efforts, visit their website at www.neuvogen.com.